{"id":553844,"date":"2021-07-21T17:44:02","date_gmt":"2021-07-21T17:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=553844"},"modified":"2021-07-21T17:44:02","modified_gmt":"2021-07-21T17:44:02","slug":"hrpositiveher2negative-breast-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hrpositiveher2negative-breast-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_553844.html","title":{"rendered":"HR-positive\/HER2-negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1626785164.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"HR-positive\/HER2-negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1626785164.jpeg\" alt=\"HR-positive\/HER2-negative Breast Cancer Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cHR-positive\/HER2-negative Breast Cancer Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the HR-positive\/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive\/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"> &ldquo;<strong>HR-positive\/HER2-negative Breast Cancer Pipeline Insight<\/strong>&rdquo;<\/a> report provides comprehensive insights about key companies&nbsp;and pipeline drugs in the HR-positive\/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive\/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the HR-positive\/HER2-negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive HR-positive\/HER2-negative Breast Cancer pipeline products.&nbsp; &nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/3cf9b06a06f3cab7139503966273f3d7.jpg\" alt=\"\" \/>&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">HR-positive\/HER2-negative Breast Cancer Pipeline Report&nbsp;&nbsp;<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp.\/Eisai, Bayer, etc., are developing therapies for the treatment of HR-positive\/HER2-negative Breast Cancer.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Emerging therapies such as <\/span><span>SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, <\/span><span>are expected to have a significant impact on the <\/span><span>&nbsp;HR-positive\/HER2-negative Breast Cancer <\/span><span>market in the coming years.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The postmenopausal breast cancer market size within the 7MM was found to be USD <\/span><span>6,315.1 <\/span><span>million in 2018.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>The <\/span><span>HR-positive\/HER2-negative Breast Cancer <\/span><span>market size shall increase during the forecast period <\/span><span>2021&ndash;2030<\/span><span>.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Among the 7MM, the US accounts for <\/span><span>80.51%<\/span><span> USD of the <\/span><span>HR-positive\/HER2-negative Breast Cancer <\/span><span>market size in 2018.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get an overview of pipeline landscape @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">HR-positive\/HER2-negative Breast Cancer Clinical Trials Analysis &nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>HR-positive\/HER2-negative breast cancer is the commonest carcinoma and also accounts for a better percentage of all breast cancers. HR-positive cancer is typically treated with hormone therapies or a combination of hormone therapies with targeted therapy to assist stop tumor growth.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>HR-positive\/HER2-negative Breast Cancer Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>SHR6390 by Jiangsu HengRui Medicine<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Elacestrant (RAD1901) by Radius Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Sacituzumab govitecan by Immunomedics<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Ipatasertib and Venclexta by Roche<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Entinostat by Syndax Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pembrolizumab by <\/span><span>Merck Sharp and Dohme&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Eribulin Mesylate by Merck Sharp and Dohme Corp.\/Eisai&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Radium-223 dichloride by Bayer<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>And others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"> HR-positive\/HER2-negative Breast Cancer Pipeline Drug Insight<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Coverage: <\/span><span>Global&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Major Players:<\/span><span> Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, <\/span><span>Merck Sharp and Dohme, <\/span><span>Merck Sharp and Dohme Corp.\/Eisai, Bayer, and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pipeline Therapies:<\/span><span> SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Pipeline Therapeutics<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Late Stage Products (Phase II\/III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Mid Stage Products (Phase II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Early Stage Products (Phase I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Preclinical Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Therapeutics Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16&nbsp;<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Market Drivers and Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Future Perspectives and Conclusion<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>HR-positive\/HER2-negative Breast Cancer Analyst Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>20<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\"><strong><span id=\"docs-internal-guid-3e05a575-7fff-abfd-dfa8-f5be92885617\"><span id=\"docs-internal-guid-3e05a575-7fff-abfd-dfa8-f5be92885617\">Get a customized pipeline report @<\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\"><span id=\"docs-internal-guid-3e05a575-7fff-abfd-dfa8-f5be92885617\">HR-positive\/HER2-negative Breast Cancer Drugs Pipeline Report<\/span><\/a><\/span><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hrpositiveher2negative-breast-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hrpositiveher2negative-breast-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cHR-positive\/HER2-negative Breast Cancer Pipeline Insight\u201d report provides comprehensive insights about key companies and pipeline drugs in the HR-positive\/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive\/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hrpositiveher2negative-breast-cancer-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_553844.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-553844","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=553844"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553844\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=553844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=553844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=553844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}